Japan first to approve Novartis' blockbuster hopeful Cosentyx; Bayer, Hospira win FDA nods;

> Japan has approved Novartis' ($NVS) Cosentyx as a treatment for psoriasis and psoriatic arthritis. Release

> The FDA has green-lighted Bayer's Gadavist injection as the first magnetic resonance contrast agent for pediatric patients less than 2 years of age. Release

> The FDA has given Hospira ($HSP) a thumbs-up for its analgesic Dyloject injection, a treatment for pain management. Release

> Angelini will market Ariad's ($ARIA) Iclusig in Eastern Europe. Report

> Pfizer ($PFE) has granted Georgia State $850,000 to partner with Chinese health officials to expand tobacco control efforts in China's major cities. More

> The Asia-Pacific market for Type 2 diabetes treatments will hit $10.5 billion by 2020, GBI Research predicts. Release

And Finally... The Gates Foundation is using art to encourage vaccination. Story (sub. req.)

Suggested Articles

Roche’s Tecentriq didn't repeat its prior TNBC success when tested in tandem with chemo med paclitaxel in previously untreated metastatic patients.

Alexion Pharmaceuticals names its first chief diversity officer as the rare disease specialist looks to cultivate diversity and inclusion.

Back in 2015, GlaxoSmithKline traded away its marketed cancer assets and began rebuilding its oncology pipeline. Those efforts have finally paid off.